Penumbra Inc (New York Stock Exchange:PEN)
| Market Cap | $12.58B+7.0% |
| Revenue (ttm) | $1.56B+17.0% |
| Net Income | $157.02M-4.3% |
| EPS | $3.97-5.0% |
| Shares Out | 39.41M |
| PE Ratio | 79.98 |
| Forward PE | 53.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,407 |
| Open | $319.91 |
| Previous Close | $320.01 |
| Day's Range | $319.02 - $320.32 |
| 52-Week Range | $284.95 - $362.41 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | $320.00(+0.28%) |
| Earnings Date | Feb 24, 2027 |
About PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 24, 2027Earnings report
$PEN stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of PEN by members of U.S. Congress
| Lisa C. McClainHouse / R | Sale$1.00K – $15.00K | Jul 10, 2025 |
Recently reported changes in PEN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PEN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PEN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PEN Revenue by Segment or Geography
| Revenue from contract with customer | $410.14M | 50.00% |
| Thrombectomy | $279.16M | 34.03% |
| Embolization and Access | $130.99M | 15.97% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PEN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PEN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PEN
| IJHiShares Core S&P Mid-Cap ETF | $454.22M |
| VTIVanguard Morningstar Total Stock Market ETF | $299.06M |
| VBVanguard Morningstar Small-Cap ETF | $267.59M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $149.76M |
| VXFVanguard Extended Market ETF | $142.17M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | $94.37M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PEN’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BTAL | AGF U.S. Market Neutral Anti-Beta Fund | 3.97% |
| EVNT | AltShares Event-Driven ETF | 2.56% |
| ARB | AltShares Merger Arbitrage ETF | 2.50% |
| MDEV | First Trust Indxx Medical Devices ETF | 1.88% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 1.75% |
| IHI | iShares U.S. Medical Devices ETF | 1.57% |
| AUSF | Global X - Adaptive U.S. Factor ETF | 1.55% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.52% |
| MNTL | Tema Neuroscience And Mental Health ETF | 1.46% |
| ZUH.TO | BMO Equal Weight US Health Care Hedged to CAD Index ETF | 1.06% |
| RFG | Invesco S&P MidCap 400 Pure Growth ETF | 1.05% |
| ZHU.TO | BMO Equal Weight US Health Care Index ETF | 1.03% |
Weight is the stock’s share of each fund’s holdings.
